SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Krueger Nancy

(Last) (First) (Middle)
3545 JOHN HOPKINS COURT, SUITE 250

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/06/2019
3. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ LIFE ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 14,999 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 10/10/2024 Common Stock 35,608 17.74 D
Stock Option (right to buy) (2) 04/17/2025 Common Stock 6,286 9.15 D
Stock Option (right to buy) (3) 05/06/2025 Common Stock 8,800 14 D
Stock Option (right to buy) (4) 10/01/2025 Common Stock 17,000 10.24 D
Stock Option (right to buy) (5) 01/27/2026 Common Stock 20,000 6.14 D
Stock Option (right to buy) (6) 09/13/2026 Common Stock 36,500 3.06 D
Stock Option (right to buy) (7) 02/07/2027 Common Stock 35,000 3.3 D
Stock Option (right to buy) (8) 02/06/2028 Common Stock 50,000 3.3 D
Stock Option (right to buy) (9) 05/16/2028 Common Stock 50,000 0.85 D
Restricted Stock Units (10) (10) Common Stock 25,000 (11) D
Explanation of Responses:
1. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning November 7, 2014. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
2. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning May 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
3. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning June 6, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
4. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning November 1, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
5. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning February 1, 2016. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
6. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning October 13, 2016. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
7. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning March 7, 2017. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
8. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning March 6, 2018. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
9. The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning June 16, 2018. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.
10. The restricted stock units (RSUs) are scheduled to vest in two equal annual installments beginning May 16, 2019, such that this grant will be fully vest on May 16, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
11. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Remarks:
Nancy D. Krueger 02/08/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.